43 results about "Immune dysregulation" patented technology

The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Provided are vaccines, methods of making the vaccines and methods for administering the vaccines for immunotherapy of an individual bearing, or at risk for developing, solid nonlymphoid tumor. The vaccine comprises an immunotherapeutic composition and tumor-associated antigen, and may further comprise one or more of an immunomodulator or a pharmaceutically acceptable carrier. A method of immunotherapy of an individual comprises administering to the individual an amount of the vaccine effective to suppress a TH2 response, and to induce a TH1 response against solid nonlymphoid tumor, in an individual having a TH2/TH1 imbalance.

The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.

The present invention relates to methods of treating or decreasing the likelihood of developing a disorder associated with immune misregulation, such as, an autoimmune disorder, or viral or virus-associated disorder in a subject including administering to the subject a composition comprising an activator of a CCCH zinc finger-containing PARP, such as, PARP13 or PARP12. The present invention also relates to methods of treating a TRAIL-resistant disorder, such as, TRAIL-resistant cancer including administering to the subject a composition comprising an activator of a CCCH zinc finger-containing PARP, such as, PARP13 or PARP12. The present invention further relates to methods of modulating a CCCH zinc finger-containing PARP-RNA interaction including contacting a CCCH zinc finger-containing PARP protein or a CCCH zinc finger-containing PARP fusion protein with a CCCH zinc finger-containing PARP activator.

This invention discloses cannabinoid derivatives and pharmaceutical uses thereof.

The invention relates to an application to preparing a medicine for treating a disease caused by immunity imbalance of a mammal with a tumulosic acid compound K2-1 or other pharmaceutically acceptable salt thereof as an active ingredient, wherein the disease caused by immunity imbalance is allergy, and the allergy is allergic asthma; and the tumulosic acid compound K2-1 is of a structure represented by a chemical formula shown in the specification, wherein R2=OH.

This invention discloses cannabinoid derivatives and pharmaceutical uses thereof including the treatment of HIV and diseases of immune dysregulation.

The present invention relates to methods of treating periodontal disease.

Methods for preparing populations of hematopoietic stem cells (HSCs), e.g., autologous and/or allogenic HSCs, using mechanical stretching or transient receptor potential cation channel-subfamily vanilloid member 4 (Trpv4) agonists, and methods of use of the HSCs in transplantation are provided. Specifically, the methods comprising providing population cells comprising hemogenic endothelial (HE) cells, contacting the HE cells with an amount of an agonist of Trpv4; and/or subjecting the cells to cyclic 2-dimensional stretching, for a time and under conditions sufficient to stimulating endothelial-to-HSC transition. Further disclosed are methods of treating malignant or non-malignant hematologic, metabolic, or immune disorders comprising administering to a subject a therapeutically effectiveamount of HSCs obtained by the methods.

The invention discloses azobenzene derivatives and their preparation method, pharmaceutical composition and use and relates to azobenzene derivatives shown in the formula I and their medicinal salts and preparation method, a composition containing one or more of the azobenzene derivatives and a use of the azobenzene derivatives in inflammation disease, immunization imbalance and tumor disease treatment.

The invention provides an application of CST1 in prevention and/or treatment of liver immune disorder diseases. Specifically, the invention provides an application of a CST1 gene, or a protein thereof or an accelerant thereof, the CST1 gene, or the protein thereof or the accelerant thereof is used for preparing a composition or a preparation, and the composition or the preparation is used for preventing and/or treating liver immune disorder diseases. The invention also accidentally finds that the CST1 protein and the CST1 overexpression-based cell therapy have great potential for the treatment of acute hepatic failure.

The invention discloses N'-aryl formyl o-pyridine hydrazide derivatives represented by the formula I and pharmaceutically acceptable salts and preparation methods thereof, a composition containing one or more of the compounds, and an application of the compounds in treatment of protein kinase related diseases, such as immune disorder and tumor disease.

The invention provides a group of long-chain non-coding RNA (lncRNA) markers for tumor immune typing, and the group of long-chain non-coding RNA markers totally comprises 49 lncRNAs. The invention also provides a tumor immune typing method based on the above lncRNA markers. According to the method, 49 lncRNAs are grouped and are combined with the expression quantity of cytotoxic T lymphocytes (CTL) to further classify patients into four groups, including an immune-active class, an immune-exclusion class, an immune-dysfunctional class and an immune-desert class by means of hierarchical clustering. The tumor immune subtype classification method provided by the invention has very strong correlation with prediction of the overall survival rate and the reactivity of anti-tumor immunotherapy, and has the characteristics of high objectivity, accuracy and repeatability. Establishment of the classification method provides a prediction index for the curative effect and the prognosis of the anti-immunotherapy of malignant tumor patients.

The present invention relates to a pharmaceutical composition, a cosmetic composition, or a health functional food, which are capable of effectively alleviating allergic diseases by inhibiting the secretion of Thymic stromal lymphopoietin (TSLP) and inhibiting TSLP, and which include, as an active ingredient, a compound represented by chemical formula 1 of the present invention or a pharmaceutically acceptable salt. Accordingly, the composition has an excellent effect for inhibiting the secretion of TSLP, which is an immune reaction factor, and thus is superior for alleviating allergic diseases caused by an imbalance in the immune system.

Compositions comprising components prepared from Gram positive bacteria such as Gram positive facultative intracellular bacteria, for example mycobacteria, including extended freeze-dried killed Gram positive bacteria, their method of preparation and their use in humans and animals, for the prevention and/or the treatment of disorders comprising an immune dysregulation such as cancer, autoimmune diseases, allergy and tuberculosis.